Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025606) COMPOSITIONS FOR USE FOR TREATING CUTANEOUS LEISHMANIASIS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/025606 International Application No.: PCT/EP2018/071168
Publication Date: 07.02.2019 International Filing Date: 03.08.2018
IPC:
A61K 31/351 (2006.01) ,A61K 31/045 (2006.01) ,A61P 33/02 (2006.01) ,A61K 31/355 (2006.01) ,A61K 31/245 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
35
having six-membered rings with one oxygen as the only ring hetero atom
351
not condensed with another ring
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
045
Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
33
Antiparasitic agents
02
Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
35
having six-membered rings with one oxygen as the only ring hetero atom
352
condensed with carbocyclic rings, e.g. cannabinols, methantheline
353
3,4-Dihydrobenzopyrans, e.g. chroman, catechin
355
Tocopherols, e.g. vitamin E
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
215
of carboxylic acids
235
having an aromatic ring attached to a carboxyl group
24
having an amino or nitro group
245
Amino benzoic acid types, e.g. procaine, novocaine
Applicants:
BIONOOX SA [CH/CH]; Route de la Corniche 2 c/o BDO SA 1066 Epalinges, CH
Inventors:
STARCKMANN, Edward; CH
Agent:
ICOSA; 83 avenue Denfert-Rochereau 75014 Paris, FR
Priority Data:
17306038.503.08.2017EP
Title (EN) COMPOSITIONS FOR USE FOR TREATING CUTANEOUS LEISHMANIASIS
(FR) COMPOSITIONS DESTINÉES À ÊTRE UTILISÉES POUR LE TRAITEMENT DE LA LEISHMANIOSE CUTANÉE
Abstract:
(EN) The invention relates to the use of a composition comprising dihydroquercetin, alpha-tocopherol, and optionally bisabolol and/or a compound of formula (I) for use in the treatment of leishmaniasis, especially cutaneous leishmaniasis. The invention further relates to the use of such a composition for treating inflammation induced by leishmaniasis, especially cutaneous leishmaniasis. The invention also relates to a method for treating leishmaniasis, especially cutaneous leishmaniasis, and/or the associated inflammation by administering an effective amount of a composition comprising dihydroquercetin, bisabolol, alpha-tocopherol and optionally bisabolol and/or a compound of formula (I) to a subject in need thereof.
(FR) L'invention concerne l'utilisation d'une composition comprenant de la dihydroquercétine, de l'alpha-tocophérol et éventuellement du bisabolol et/ou un composé de formule (I) destiné à être utilisé dans le traitement de la leishmaniose, notamment de la leishmaniose cutanée. L’invention concerne également l'utilisation d'une telle composition dans le traitement de l'inflammation induite par la leishmaniose, en particulier la leishmaniose cutanée. L'invention concerne en outre une méthode de traitement de la leishmaniose, en particulier de la leishmaniose cutanée et/ou de l'inflammation associée par l'administration d'une quantité efficace d'une composition comprenant de la dihydroquercétine, du bisabolol, de l’alpha-tocophérol et éventuellement du bisabolol et/ou un composé de formule (I) à un sujet qui en a besoin.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)